PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).

Xuewei Ding, Han Liang, Bin Li et al.|Journal of Clinical Oncology|2023

Cited by 30